Scientists are now tracing climate variables to forecast
future outbreaks of the disease (ClimateWire, Sept. 20, 2013).
The intent is to accelerate progress towards preventing and reducing
future outbreaks of disease, detecting threats early and providing rapid, effective, coordinated responses to emerging threats.
My PhD career, funded with HELIX, will involve looking at how much society is willing to pay to confront
future outbreaks of diseases like malaria.
Not exact matches
Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability
of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost
of accommodating, announced increases in the build rates
of certain aircraft; 6) the effect on aircraft demand and build rates
of changing customer preferences for business aircraft, including the effect
of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result
of global economic uncertainty or otherwise; 8) the effect
of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution
of key milestones such as the receipt
of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation
of our announced acquisition
of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate,
future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability
of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk
of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production
of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts
of terrorism; 14) any adverse impact on the demand for air travel or our operations from the
outbreak of diseases or epidemic or pandemic
outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact
of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition
of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect
of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect
of changes in tax law, such as the effect
of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations
of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect
of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability
of raw materials and purchased components; 23) our ability to recruit and retain a critical mass
of highly - skilled employees and our relationships with the unions representing many
of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment
of interest on, and principal
of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness
of any interest rate hedging programs; 28) the effectiveness
of our internal control over financial reporting; 29) the outcome or impact
of ongoing or
future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition
of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result
of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks
of doing business internationally, including fluctuations in foreign current exchange rates, impositions
of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
The
outbreak of infectious
diseases like SARS and bird flu in Asia in recent years has increased the urgency
of Canadian governments at all levels to enhance their capacity to cope with possible
future outbreaks in this country.
New York City Mayor Bill de Blasio has signed legislation aimed at preventing
future outbreaks of Legionnaires»
Disease.
Legislation passed in the wake
of that
outbreak requires building owners to register their cooling towers with the city, and City Council Speaker Melissa Mark - Viverito said members would now see if there are any additional steps they can take to help guard against
future cases
of Legionnaires»
disease.
With the
outbreak contained, Mr. de Blasio said attention was now turning on how to prevent
future outbreaks of Legionnaires»
disease with legislation that will require inspections and cleaning
of cooling towers — an area where he and Mr. Cuomo had originally sparred but have now landed on the same page.
«This summer's
outbreak of Legionnaires»
disease caused concern in communities across the state, and today we are moving forward to help prevent
future outbreaks and keep our neighborhoods safe,» Mr. Cuomo said in a statement.
LEGIONNAIRES» FALLOUT: Monday morning at City Hall, Mayor Bill de Blasio will hold a bill - signing ceremony, beginning at 10 a.m. (full details below), and then, around noon, «the Mayor, Speaker Melissa Mark - Viverito and elected officials will host a press conference to introduce new legislation to reduce
future risk
of Legionnaires»
disease, and provide an update on the containment
of the
outbreak,» according to the mayor's public schedule.
Pandemic preparedness is not only critical because
of the threat
of a
future pandemic or an
outbreak of an emerging infectious
disease, but also because school preparedness for all types
of disasters, including biological events, is mandated by the U.S. Department
of Education.
Using a vaccine to take a
disease out
of the mix could leave a population vulnerable to
future outbreaks should the vaccine become ineffective or stop being used.
The way we prepare for, and respond to,
future outbreaks of Ebola and other infectious
diseases needs to be strengthened.»
Preventing a
future crisis like Ebola requires better diagnostic tools and
disease surveillance networks so that
outbreaks can be identified and stopped before they get out
of hand.
Safe and effective vaccines could help end the ongoing Ebola virus
disease epidemic in parts
of West Africa and stop
future outbreaks of the virus.
In September 2015 the Science Media Centre submitted written evidence to the Commons Science and Technology Select Committee on what lessons have been drawn from the Ebola
outbreak last year concerning the use
of scientific advice in the UK for similar
disease outbreak emergencies in
future.
While this study focused on the foot - and - mouth
outbreak, the method could also be used for planning purposes in the event
of a
future outbreak of other infectious
diseases in livestock.
The complex viromes
of different human as well as wild and domesticated animal populations are also characterized to allow
future changes associated with
disease outbreak to be rapidly identified.
An international effort to analyze the entire database
of Ebola virus genomes from the 2013 — 2016 West African epidemic reveals insights into factors that sped or slowed the rampage and calls for using real - time sequencing and data - sharing to contain
future viral
disease outbreaks.
The
future of infectious
disease surveillance and
outbreak response is trending towards smaller hand - held solutions for point -
of - need pathogen detection.
Future pandemic flu
outbreaks would be ranked, like hurricanes, on a scale
of 1 to 5, and school closures
of up to three months would be recommended for more severe
outbreaks, according to a planning guide released jointly last week by the Department
of Education, the Department
of Health and Human Services, and the U.S. Centers for
Disease Control and Prevention.
Many diagnostic tests can be
of tremendous value in helping shelters prevent
future outbreaks of infectious
disease.
The program teaches current and
future veterinarians to treat and prevent
disease; provides high quality care to sick, injured, and abused animals; consults on population health and protocols, including diagnostic assistance in instances
of disease outbreaks; helps reduce pet overpopulation and euthanasia through spay / neuter programs; and improves animal health through education
of new and existing pet owners.
There are multiple studies associating extreme precipitation events with waterborne
disease outbreaks and strong climatological evidence for increasing frequency and intensity
of extreme precipitation events in the
future.
With climate change, we may start seeing
outbreaks of diseases occurring in the near
future.
My research entails measuring the benefits
of avoiding such
disease outbreaks in the
future.
Outbreaks of native insects and
diseases are expected to occur in response to
future warming temperatures and a drier environment, but tree mortality is not likely to be uniformly distributed across the landscape.
Plant genetic diversity also has the potential to provide traits that can help meet
future challenges, such as the need to adapt crops to changing climatic conditions or
outbreaks of disease.»
They stress the importance
of maintaining a diversity within each crop, because: «Plant genetic diversity also has the potential to provide traits that can help meet
future challenges, such as the need to adapt crops to changing climatic conditions or
outbreaks of disease.»